Skip to content
2000
image of Liver Diseases Associated with Insulin Resistance: Exploring the Therapeutic Potential of the Green-derived Bioactive Lipopeptide Surfactin for the Prevention and Amelioration of Non-alcoholic Fatty Liver Disease

Abstract

Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of fat in hepatocytes and is gradually becoming a global epidemic that can cause serious health problems. NAFLD can lead to hepatocellular carcinoma (HCC), cirrhosis, and death. The major causes are considered obesity, insulin resistance (IR), a family history of the condition, an inactive lifestyle, and consuming a high-fat diet. Due to IR, the body barely reacts to insulin, mainly during insulin-mediated glucose uptake, with normal or raised insulin levels. The use of several drugs to combat IR and NAFLD has led to increased cases of edema, weakened bones, and heart failure as side effects. Bioactive peptides can potentially enhance glucose homeostasis and insulin sensitivity by inducing several target pathways in the body, such as the digestion of carbohydrates, glucose uptake, the modification of adipose tissue, and insulin secretion. The lipopeptide surfactin exhibits a diverse array of biological activities, such as antibacterial, tissue modification, and antiviral effects. Recently, notable attention has been paid to microbe-derived peptides due to their alleviating effect on IR and NAFLD. In conclusion, emerging research on surfactin suggests a potential therapeutic impact in mitigating NAFLD through improving IR progression.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775411170251201151240
2026-01-22
2026-02-26

  • From This Site

    /content/journals/cdrr/10.2174/0125899775411170251201151240
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ko E. Yoon E.L. Jun D.W. Risk factors in nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2023 29 S79 S85 [Suppl. 10.3350/cmh.2022.039836517003
    [Google Scholar]
  2. Hegazy M.A. Elshafei A. Salem M.R. Ashoush O. Abdelghani A. Non-alcoholic fatty liver disease related knowledge among a sample of Egyptians: An exploratory cross-sectional study. Front. Public Health 2024 11 1290842 10.3389/fpubh.2023.129084238872989
    [Google Scholar]
  3. Petrescu M. Vlaicu S.I. Ciumărnean L. Chronic inflammation—a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. Medicina 2022 58 5 641 10.3390/medicina5805064135630058
    [Google Scholar]
  4. Basaranoglu M. Turhan N. Sonsuz A. Basaranoglu G. Mallory-Denk Bodies in chronic hepatitis. World J. Gastroenterol. 2011 17 17 2172 2177 10.3748/wjg.v17.i17.217221633525
    [Google Scholar]
  5. Weiss R. Taksali S.E. Dufour S. The “obese insulin-sensitive” adolescent: Importance of adiponectin and lipid partitioning. J. Clin. Endocrinol. Metab. 2005 90 6 3731 3737 10.1210/jc.2004‑230515797955
    [Google Scholar]
  6. Xu E. Pereira M.M.A. Karakasilioti I. Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance. Nat. Commun. 2017 8 1 14803 10.1038/ncomms1480328466852
    [Google Scholar]
  7. Jahandideh F. Wu J. A review on mechanisms of action of bioactive peptides against glucose intolerance and insulin resistance. Food Sci. Hum. Wellness 2022 11 6 1441 1454 10.1016/j.fshw.2022.06.001
    [Google Scholar]
  8. Huh Y. Cho Y.J. Nam G.E. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. J. Obes. Metab. Syndr. 2022 31 1 17 27 10.7570/jomes2202135332111
    [Google Scholar]
  9. Lonardo A. Bellentani S. Argo C.K. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig. Liver Dis. 2015 47 12 997 1006 10.1016/j.dld.2015.08.00426454786
    [Google Scholar]
  10. Macut D. Tziomalos K. Božić-Antić I. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum. Reprod. 2016 31 6 1347 1353 10.1093/humrep/dew07627076501
    [Google Scholar]
  11. Jasirwan C.O.M. Lesmana C.R.A. Hasan I. Sulaiman A.S. Gani R.A. The role of gut microbiota in non-alcoholic fatty liver disease: Pathways of mechanisms. Biosci. Microbiota Food Health 2019 38 3 81 88 10.12938/bmfh.18‑03231384519
    [Google Scholar]
  12. Mu T. Peng L. Xie X. Single nucleotide polymorphism of genes associated with metabolic fatty liver disease. J. Oncol. 2022 2022 1 6 10.1155/2022/928255735154322
    [Google Scholar]
  13. El Ray A. Asselah T. Moucari R. Insulin resistance: A major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 2013 25 4 421 427 10.1097/MEG.0b013e32835c9f6923470266
    [Google Scholar]
  14. Röder P.V. Wu B. Liu Y. Han W. Pancreatic regulation of glucose homeostasis. Exp. Mol. Med. 2016 48 3 219 10.1038/emm.2016.626964835
    [Google Scholar]
  15. Grayson B.E. Seeley R.J. Sandoval D.A. Wired on sugar: The role of the CNS in the regulation of glucose homeostasis. Nat. Rev. Neurosci. 2013 14 1 24 37 10.1038/nrn340923232606
    [Google Scholar]
  16. Meshkani R. Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem. 2009 42 13-14 1331 1346 10.1016/j.clinbiochem.2009.05.01819501581
    [Google Scholar]
  17. Kumashiro N. Erion D.M. Zhang D. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. USA 2011 108 39 16381 16385 10.1073/pnas.111335910821930939
    [Google Scholar]
  18. Sakurai Y. Kubota N. Yamauchi T. Kadowaki T. Role of insulin resistance in mafld. Int. J. Mol. Sci. 2021 22 8 4156 10.3390/ijms2208415633923817
    [Google Scholar]
  19. Zou P. Wang L. Dietary pattern and hepatic lipid metabolism. Liver Res. 2023 7 4 275 284 10.1016/j.livres.2023.11.00639958775
    [Google Scholar]
  20. Samuel V.T. Liu Z.X. Qu X. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004 279 31 32345 32353 10.1074/jbc.M31347820015166226
    [Google Scholar]
  21. Czaja M.J. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol. Metab. 2010 21 12 707 713 10.1016/j.tem.2010.08.01020888782
    [Google Scholar]
  22. Zeng J. Fan J.G. Francque S.M. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterol. J. 2024 12 2 177 186 10.1002/ueg2.1252538193865
    [Google Scholar]
  23. Ziolkowska S. Binienda A. Jablkowski M. Szemraj J. Czarny P. The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease. Int. J. Mol. Sci. 2021 22 20 11128 10.3390/ijms22201112834681787
    [Google Scholar]
  24. Zeng P. Cai X. Yu X. Gong L. Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population. Sci. Rep. 2023 13 1 20470 10.1038/s41598‑023‑47269‑437993481
    [Google Scholar]
  25. Paschos P. Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Int. J. Biol. Pharm. Allied Sci. 2021 10 1 (SPECIAL ISSUE) 9 19 10.31032/IJBPAS/2021/10.1.100919240815
    [Google Scholar]
  26. Kung Y.T. Du Y.C. Huang W.T. Chen C.C. Ke L.T. Total synthesis of crystalline bovine insulin. Sci. Sin. 1965 14 11 1710 1716 [PMID: 5881570
    [Google Scholar]
  27. MacDonald-Ramos K. Michán L. Martínez-Ibarra A. Cerbón M. Silymarin is an ally against insulin resistance: A review. Ann. Hepatol. 2021 23 100255 10.1016/j.aohep.2020.08.07232950646
    [Google Scholar]
  28. Sanger F. Thompson E.O.P. The amino-acid sequence in the glycyl chain of insulin. 1. The identification of lower peptides from partial hydrolysates. Biochem. J. 1953 53 3 353 366 10.1042/bj0530353
    [Google Scholar]
  29. Vecchio I. Tornali C. Bragazzi N.L. Martini M. The discovery of insulin: An important milestone in the history of medicine. Front. Endocrinol. 2018 9 613 10.3389/fendo.2018.0061330405529
    [Google Scholar]
  30. Papakonstantinou E. Oikonomou C. Nychas G. Dimitriadis G.D. Effects of diet, lifestyle, chrononutrition and alternative dietary interventions on postprandial glycemia and insulin resistance. Nutrients 2022 14 4 823 10.3390/nu1404082335215472
    [Google Scholar]
  31. Galicia-Garcia U. Jebari S. Larrea-Sebal A. Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights. Int. J. Mol. Sci. 2020 21 13 4725 10.3390/ijms2113472532630698
    [Google Scholar]
  32. Chang A.M. Halter J.B. Aging and insulin secretion. Am. J. Physiol. Endocrinol. Metab. 2003 284 1 E7 E12 10.1152/ajpendo.00366.200212485807
    [Google Scholar]
  33. Gabriely I. Ma X.H. Yang X.M. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: An adipokine-mediated process? Diabetes 2002 51 10 2951 2958 10.2337/diabetes.51.10.295112351432
    [Google Scholar]
  34. Zhao X. An X. Yang C. Sun W. Ji H. Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol. 2023 14 1149239 10.3389/fendo.2023.114923937056675
    [Google Scholar]
  35. Ashraf A. Palakkott A. Ayoub M.A. Anti-insulin receptor antibodies in the pathology and therapy of diabetes mellitus. Curr. Diabetes Rev. 2021 17 2 198 206 10.2174/157339981666620060412234532496987
    [Google Scholar]
  36. Hall C. Yu H. Choi E. Insulin receptor endocytosis in the pathophysiology of insulin resistance. Exp. Mol. Med. 2020 52 6 911 920 10.1038/s12276‑020‑0456‑332576931
    [Google Scholar]
  37. Porrini E. Delgado P. Bigo C. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am. J. Kidney Dis. 2006 48 1 134 142 10.1053/j.ajkd.2006.04.07816797396
    [Google Scholar]
  38. Okasha H. Fundamental uses of peptides as a new model in both treatment and diagnosis. Recent Pat. Biotechnol. 2024 18 2 110 127 10.2174/187220831766623051214350838282442
    [Google Scholar]
  39. Muheem A. Shakeel F. Jahangir M.A. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm. J. 2016 24 4 413 428 10.1016/j.jsps.2014.06.00427330372
    [Google Scholar]
  40. Zhang Y. Wang C. Zhang W. Li X. Bioactive peptides for anticancer therapies. Biomater. Transl. 2023 4 1 5 17 10.12336/biomatertransl.2023.01.00337206303
    [Google Scholar]
  41. Wang G. Vaisman I.I. van Hoek M.L. Machine Learning prediction of antimicrobial peptides. Methods Mol. Biol. 2022 2405 1 37 10.1007/978‑1‑0716‑1855‑4_135298806
    [Google Scholar]
  42. Binda E. Marinelli F. Marcone G. Old and new glycopeptide antibiotics: Action and resistance. Antibiotics 2014 3 4 572 594 10.3390/antibiotics304057227025757
    [Google Scholar]
  43. Yim G. Thaker M.N. Koteva K. Wright G. Glycopeptide antibiotic biosynthesis. J. Antibiot. 2014 67 1 31 41 10.1038/ja.2013.11724220108
    [Google Scholar]
  44. Klinker K.P. Borgert S.J. Beyond vancomycin: The tail of the lipoglycopeptides. Clin. Ther. 2015 37 12 2619 2636 10.1016/j.clinthera.2015.11.00726658277
    [Google Scholar]
  45. Fernández J. Gustot T. Management of bacterial infections in cirrhosis. J. Hepatol. 2012 56 Suppl. 1 S1 S12 10.1016/S0168‑8278(12)60002‑622300459
    [Google Scholar]
  46. Strieker M. Tanović A. Marahiel M.A. Nonribosomal peptide synthetases: Structures and dynamics. Curr. Opin. Struct. Biol. 2010 20 2 234 240 10.1016/j.sbi.2010.01.00920153164
    [Google Scholar]
  47. Da Silveira E. A review on anti-inflammatory activity of phenylpropanoids found in essential oils. Molecules 2014 19 2 1459 1480 10.3390/molecules1902145924473208
    [Google Scholar]
  48. Zambry N.S. Rusly N.S. Awang M.S. Md Noh N.A. Yahya A.R.M. Production of lipopeptide biosurfactant in batch and fed-batch Streptomyces sp. PBD-410L cultures growing on palm oil. Bioprocess Biosyst. Eng. 2021 44 7 1577 1592 10.1007/s00449‑021‑02543‑533687550
    [Google Scholar]
  49. Pilz M. Cavelius P. Qoura F. Awad D. Brück T. Lipopeptides development in cosmetics and pharmaceutical applications: A comprehensive review. Biotechnol. Adv. 2023 67 108210 10.1016/j.biotechadv.2023.10821037460047
    [Google Scholar]
  50. Seydlová G. Svobodová J. Review of surfactin chemical properties and the potential biomedical applications. Open Med. 2008 3 2 123 133 10.2478/s11536‑008‑0002‑5
    [Google Scholar]
  51. Kraas F.I. Helmetag V. Wittmann M. Strieker M. Marahiel M.A. Functional dissection of surfactin synthetase initiation module reveals insights into the mechanism of lipoinitiation. Chem. Biol. 2010 17 8 872 880 10.1016/j.chembiol.2010.06.01520797616
    [Google Scholar]
  52. Zhen C. Ge X.F. Lu Y.T. Liu W.Z. Chemical structure, properties and potential applications of surfactin, as well as advanced strategies for improving its microbial production. AIMS Microbiol. 2023 9 2 195 217 10.3934/microbiol.202301237091822
    [Google Scholar]
  53. Chen Z. Yu R. Xiong Y. Du F. Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017 16 1 203 10.1186/s12944‑017‑0572‑929037210
    [Google Scholar]
  54. Chen X. Lu Y. Shan M. Zhao H. Lu Z. Lu Y. A mini-review: Mechanism of antimicrobial action and application of surfactin. World J. Microbiol. Biotechnol. 2022 38 8 143 10.1007/s11274‑022‑03323‑335718798
    [Google Scholar]
  55. Crovella S. de Freitas L.C. Zupin L. Surfactin bacterial antiviral lipopeptide blocks in vitro replication of SARS-CoV-2. Appl. Microbiol. 2022 2 3 680 687 10.3390/applmicrobiol2030052
    [Google Scholar]
  56. Wu Y.S. Ngai S.C. Goh B.H. Chan K.G. Lee L.H. Chuah L.H. Anticancer activities of surfactin potential application of nanotechnology assisted surfactin delivery. Front. Pharmacol. 2017 8 OCT 761 10.3389/fphar.2017.0076129123482
    [Google Scholar]
  57. Wang J. He Y. Yu D. Jin L. Gong X. Zhang B. Perilla oil regulates intestinal microbiota and alleviates insulin resistance through the PI3K/AKT signaling pathway in type-2 diabetic KKAy mice. Food Chem. Toxicol. 2020 135 110965 10.1016/j.fct.2019.11096531743741
    [Google Scholar]
  58. Wang Q. Li W. He Y. Novel antioxidative peptides from the protein hydrolysate of oysters (Crassostrea talienwhanensis). Food Chem. 2014 145 991 996 10.1016/j.foodchem.2013.08.09924128574
    [Google Scholar]
  59. Tang C. Ding R. Sun J. Liu J. Kan J. Jin C. The impacts of natural polysaccharides on intestinal microbiota and immune responses – A review. Food Funct. 2019 10 5 2290 2312 10.1039/C8FO01946K31032827
    [Google Scholar]
  60. Tang C. Meng F. Pang X. Protective effects of Lactobacillus acidophilus NX2-6 against oleic acid-induced steatosis, mitochondrial dysfunction, endoplasmic reticulum stress and inflammatory responses. J. Funct. Foods 2020 74 104206 10.1016/j.jff.2020.104206
    [Google Scholar]
  61. Tang C. Kong L. Shan M. Lu Z. Lu Y. Protective and ameliorating effects of probiotics against diet-induced obesity: A review. Food Res. Int. 2021 147 110490 10.1016/j.foodres.2021.11049034399486
    [Google Scholar]
  62. Qi X. Liu W. He X. Du C. A review on surfactin: molecular regulation of biosynthesis. Arch. Microbiol. 2023 10.1007/s00203‑023‑03652‑3
    [Google Scholar]
  63. Chen X Zhao H Meng F Ameliorated effects of a lipopeptide surfactin on insulin resistance in vitro and in vivo. Food Sci Nutr. 2022 10 7 2455 2469 10.1002/fsn3.285235844917
    [Google Scholar]
  64. Zhang L. Gao Z. Zhao X. Qi G. A natural lipopeptide of surfactin for oral delivery of insulin. Drug Deliv. 2016 23 6 2084 2093 10.3109/10717544.2016.115374526982158
    [Google Scholar]
  65. Wang S. Shi J. Peng Y. Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: A real-world single-centre study. Cardiovasc. Diabetol. 2021 20 1 82 10.1186/s12933‑021‑01274‑x33888131
    [Google Scholar]
  66. Zouari R. Hamden K. Feki A.E. Protective and curative effects of Bacillus subtilis SPB1 biosurfactant on high-fat-high-fructose diet induced hyperlipidemia, hypertriglyceridemia and deterioration of liver function in rats. Biomed. Pharmacother. 2016 84 323 329 10.1016/j.biopha.2016.09.02327665478
    [Google Scholar]
/content/journals/cdrr/10.2174/0125899775411170251201151240
Loading
Liver Diseases Associated with Insulin Resistance: Exploring the Therapeutic Potential of the Green-derived Bioactive Lipopeptide Surfactin for the Prevention and Amelioration of Non-alcoholic Fatty Liver Disease
Bentham Science Publishers ; https://doi.org/10.2174/0125899775411170251201151240
/content/journals/cdrr/10.2174/0125899775411170251201151240
/content/journals/cdrr/10.2174/0125899775411170251201151240
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: bioactive peptide ; NAFLD ; IR ; green synthesis ; HCC ; Bacillus spp.

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test